← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cellectar Biosciences, Inc.
Newton, MA
$6,436,819
Total funding
4
Grants
Funding over time
peak $2M · FY2007–23$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,436,819 · 4
By mechanism
R44$3,994,487 · 2
N43$2,292,085 · 1
R41$150,247 · 1
Investigators at Cellectar Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
IGF::OT::IGF I-125-CLR1404 AS A (NEO) ADJUVANT TREATMENT OPTION FOR TRIPLE-NEGATIVE BREAST CANCER$1,999,370
N43 · FY2016 · CA
A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade Glioma$1,034,797
R44 · FY2022 · CA
A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade Glioma$965,201
R44 · FY2023 · CA
An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia$763,080
R44 · FY2021 · CA
An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia$755,603
R44 · FY2022 · CA
An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia$475,806
R44 · FY2023 · CA
IGF::OT::IGF I-125-CLR1404 AS A (NEO) ADJUVANT TREATMENT OPTION FOR TRIPLE-NEGATIVE BREAST CANCER$292,715
N43 · FY2015 · CA
PRECLINICAL DEVELOPMENT OF A GLUTATHIONE BASED CANCER DRUG$150,247
R41 · FY2007 · CA